GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix
Executive Summary
GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.
You may also be interested in...
India’s Interim Budget Pushes Innovation, Green Production, HPV Vaccination
India’s interim budget 2024 hikes allocation for production-linked incentive schemes in pharmaceuticals, supports biotech start-ups - particularly green ones- and sets the right note for inclusion of HPV vaccination in the country’s Universal Immunization Program, one of the world's largest public health programs. How does it help?
Merck, Serum Institute Face-off Looms With HPV Vaccination Support In India’s Interim Budget
A mention in India’s interim budget of support for HPV vaccination is heartening for Serum Institute and Merck as it is seen as a precursor to the vaccine’s inclusion in the country’s Universal Immunization Program, one of the largest public health programs globally. As Serum plans to expand capacity, will Merck drop Gardasil prices for a piece of the UIP pie?
US NCI’s Gravitt On Stepping Up Cancer Control Efforts In Asia-Pacific
Dr Patti Gravitt, Deputy Director, Center for Global Health, US National Cancer Institute, in an interview with Scrip, discusses a range of strategies underway and proposed to strengthen cancer control efforts in the Asia Pacific. HPV vaccination and a regional cancer control dashboard are among the areas she highlighted.